Baird raised the firm’s price target on Ultragenyx to $57 from $50 and keeps an Outperform rating on the shares. The analyst said the thesis for our rating is largely based on valuation. However, we note that mid-to-late 2023 appears to be a more catalyst-rich time for Ultragenyx than recent years, which could also help the stock.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RARE:
- Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
- Ultragenyx reports Q4 EPS ($2.16), consensus ($2.14)
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update
- Canaccord loves these biotech stocks — and gives them upside of more than 80%
- Ultragenyx assumed with a Buy at Canaccord